OXiGENE tillkännager offentliggörandet av prekliniska uppgifter om OXi4503
June 01, 2010 09:47 ET
|
Oxigene, Inc.
Södra San Francisco, Kalifornien, 1 juni, 2010 (GLOBE Newswire) -- OXiGENE,
Inc. (Nasdaq: OXGN) (Stockholm: OXGN), ett biopharma företag som strävar efter
att upptäcka och utveckla nya och förbättrade...
OXiGENE Announces Publication of Preclinical Data on OXi4503 Demonstrating Potent Anti-Leukemic Effects
May 27, 2010 08:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., May 27, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Announces Clinical Data to be Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology
May 18, 2010 16:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., May 18, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Reports First Quarter 2010 Financial Results
May 11, 2010 16:33 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., May 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Announces First Quarter 2010 Earnings Conference Call and Webcast
May 05, 2010 08:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., May 5, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer and...
OXiGENE Applies for Voluntary Delisting From the Stockholm Exchange
April 23, 2010 02:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., April 23, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Regains Compliance With NASDAQ Listing Requirements
April 07, 2010 02:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., April 7, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Appoints Tamar D. Howson and Peter J. Langecker to Its Board of Directors
April 05, 2010 08:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., April 5, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Going Concern Opinion On Its Audited Financial Statements for 2009
March 19, 2010 08:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., March 19, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Change to Board of Directors
March 15, 2010 08:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...